Medeva shares dive on obesity drug fears

Health fears over Medeva's new anti-obesity drug, Ionamin, coupled with a warning about full-year profits, drove the share price in the UK's fourth biggest drug group down by 13 per cent to 222p yesterday.

Dr Bill Bogie, chief executive, said sales of Ionamin had collapsed to pounds 7m in the first six months of this year from pounds 21m in the second half of 1996, and would be unlikely to recover in the short term after a warning from the US drug regulator last week linking anti-obesity pills with heart failure.

Analysts were surprised by the news on Ionamin and cut full-year forecasts for group profits from pounds 120m-pounds 132m to pounds 110m-pounds 115m.

First-half sales of Ionamin, which was bought from Rhone Poulenc last year and has been sold in the US since 1959, were affected by destocking and competition.

James Culverwell, an analyst at Merrill Lynch, said: "Medeva had always said that Ionamin would be a wild card, but no one thought it would be this bad." Analysts were also concerned about Ionamin's prospects, given that Roche's Xenical anti-fat pill, a safer breed of drug, could be launched shortly.

However, Dr Bogie said he still expected growth from Ionamin. "It's not like we've bought a dead duck. The obesity market is growing."

He warned that second half profits also depended on emerging competition for Methylphenidate, the group's leading drug for hyperactivity, which grew sales by 6 per cent to pounds 54m in the half year

Medeva has more than 70 per cent of the US market for this quota-controlled and licensed drug. However, three other generic companies, Johnson Matthey, Mallinckrodt and Ganes, have obtained licences. The first new generic drug is expected to enter the market by Christmas. Dr Bogie said although sales were likely to slip by around 15 per cent next year, the quota system would prevent a rush of lower-priced generics into the market.

Dr Bogie was upbeat over other products. "People should see that we are following our strategy. I am not worried about our share price. Glaxo made a remarkable turnaround after fears over Zantac."

However analysts were sceptical. Kevin Scotcher at NatWest said: "The great hope of replacing Methylphenidate with Ionamin has gone. And whether Medeva had good follow-up drugs is unclear."

Investment column, page 24

Suggested Topics
Start your day with The Independent, sign up for daily news emails
News
i100
Arts and Entertainment
Billie Piper as Brona in Penny Dreadful
tvReview: It’s business as usual in Victorian London. Let’s hope that changes as we get further into the new series spoiler alert
Life and Style
A nurse tends to a recovering patient on a general ward at The Queen Elizabeth Hospital in Birmingham
health
News
science
Arts and Entertainment
No Offence
tvReview: No Offence has characters who are larger than life and yet somehow completely true to life at the same time spoiler alert
News
Chuck Norris pictured in 1996
people
ebooks
ebooksA celebration of British elections
Arts and Entertainment
Sarah Lucas, I SCREAM DADDIO, Installation View, British Pavilion 2015
artWhy Sarah Lucas is the perfect choice to represent British art at the Venice Biennale
News
A voter placing a ballot paper in the box at a polling station
i100
News
people
Arts and Entertainment
The Queen (Kristin Scott Thomas) in The Audience
theatreReview: Stephen Daldry's direction is crisp in perfectly-timed revival
Sport
football
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Trainee Recruitment Consultant - Swiss Banking and Finance

£20000 - £25000 per annum + Uncapped commission: SThree: Can you speak German,...

Ashdown Group: Marketing Executive - 6 month FTC - Central London

£25000 - £30000 per annum + benefits: Ashdown Group: An exciting opportunity f...

Ashdown Group: Junior Project Manager (website, web application) - Agile

£215 per day: Ashdown Group: Junior Project Manager (website, web application ...

Guru Careers: Software Engineer / Software Developer

£40-50K: Guru Careers: We are seeking an experienced Software Engineer / Softw...

Day In a Page

General Election 2015: Ed Miliband's unlikely journey from hapless geek to heart-throb

Miliband's unlikely journey from hapless geek to heart-throb

He was meant to be Labour's biggest handicap - but has become almost an asset
General Election 2015: A guide to the smaller parties, from the the National Health Action Party to the Church of the Militant Elvis Party

On the margins

From Militant Elvis to Women's Equality: a guide to the underdogs standing in the election
Amr Darrag: Ex-Muslim Brotherhood minister in exile still believes Egypt's military regime can be replaced with 'moderate' Islamic rule

'This is the battle of young Egypt for the future of our country'

Ex-Muslim Brotherhood minister Amr Darrag still believes the opposition can rid Egypt of its military regime and replace it with 'moderate' Islamic rule, he tells Robert Fisk
Why patients must rely less on doctors: Improving our own health is the 'blockbuster drug of the century'

Why patients must rely less on doctors

Improving our own health is the 'blockbuster drug of the century'
Sarah Lucas is the perfect artist to represent Britain at the Venice Biennale

Flesh in Venice

Sarah Lucas has filled the British pavilion at the Venice Biennale with slinky cats and casts of her female friends' private parts. It makes you proud to be a woman, says Karen Wright
11 best anti-ageing day creams

11 best anti-ageing day creams

Slow down the ageing process with one of these high-performance, hardworking anti-agers
Juventus 2 Real Madrid 1: Five things we learnt, including Iker Casillas is past it and Carlos Tevez remains effective

Juventus vs Real Madrid

Five things we learnt from the Italian's Champions League first leg win over the Spanish giants
Ashes 2015: Test series looks a lost cause for England... whoever takes over as ECB director of cricket

Ashes series looks a lost cause for England...

Whoever takes over as ECB director of cricket, says Stephen Brenkley
Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

Fishing is on Nigel Farage's mind

Ukip leader casts a line to the disaffected
Who is bombing whom in the Middle East? It's amazing they don't all hit each other

Who is bombing whom in the Middle East?

Robert Fisk untangles the countries and factions
China's influence on fashion: At the top of the game both creatively and commercially

China's influence on fashion

At the top of the game both creatively and commercially
Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

The man known as GOD has a reputation for getting the job done

Lord O'Donnell's three principles of rule
Rainbow shades: It's all bright on the night

Rainbow shades

It's all bright on the night
'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

Bread from heaven

Dutch survivors thank RAF for World War II drop that saved millions
Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

How 'the Axe' helped Labour

UK will be 'run for the wealthy and powerful' if Tories retain power